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Background: The role and relationship between pro- and anti-inflammatory cytokines represents one of the least
studied aspects of the pathogenesis of community-acquired pneumonia (CAP). The aim of the present study was to
evaluate pro- and anti-inflammatory cytokines at both local (lung) and systemic (blood) levels and their relationship
with the severity of the disease on admission and time for a patient to reach clinical stability during hospitalisation.
Methods: This was an observational, prospective, cohort study of hospitalised patients with a diagnosis of CAP at the IRCCS
Policlinico Hospital, Milan, Italy, between April 2010 and January 2012. Ten pro-inflammatory cytokines (interleukin [IL]-1,
IL-1α, IL-1β, IL-2, IL-6, IL-8, tumor necrosis factor [TNF]α and interferon [IFN]γ) and anti-inflammatory cytokines (IL-4 and IL-10)
were measured in both serum and exhaled breath condensate within 24 h after hospital admission.
Results: A total of 74 patients (median age: 76 years; gender: 61 % male) were enrolled. The anti- to pro-inflammatory
cytokine ratio was reduced in patients with severe disease on admission and prolonged time to reach clinical stability. This
was due to lower levels of anti-inflammatory cytokines in the exhaled breath condensate and higher levels of
pro-inflammatory cytokines in serum.
Conclusions: Dis-regulation between pro- and anti-inflammatory pathways might be a part of the pathogenic mechanisms
that lead to severe infection and worse early clinical outcomes in CAP patients.
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Community-acquired pneumonia (CAP) still represents a
leading cause of death among infectious diseases, with
mortality rates that have not decreased since the introduc-
tion of antibiotics in the early 20th century [1–3]. Re-
cently, special attention has been focused on the double
role that inflammation plays in the pathogenesis of this
disease. On one hand, inflammation is part of the host’s
protective immune response against microorganisms; on
the other hand, if excessive, inflammation can be detri-
mental and increases patients’ morbidity and mortality [4].
Previous studies taught us that, in patients with pneu-
monia, a rise in systemic pro-inflammatory cytokines* Correspondence: stefano.aliberti@unimi.it
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and increases levels of lung injury [5–8]. However,
most of these data evaluated cytokines in serum,
while the presence and characterisation of inflamma-
tion in the lung has not been fully explored. When
inflammation was investigated in bronchoalveolar lav-
age (BAL) and blood of patients with severe CAP, an
increase in cytokine levels was found to be variably
associated with increased lung injury, multi-organ fail-
ure, and mortality [9, 10]. Since BAL is an invasive
technique, exhaled breath condensate (EBC) has been
recently used to evaluate non-invasive inflammatory
patterns in some respiratory diseases [11, 12], not in-
cluding pneumonia.
The relationship between pro- and anti-inflammatory
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anti-inflammatory responses seems to be associated with
respiratory failure and mortality in patients with
Pneumocystis jirovecii pneumonia [13]. We hypothesise
that an imbalanced anti- to pro-inflammatory cytokine
ratio in patients with CAP on hospital admission might
be related to a higher severity of the disease on admis-
sion and a prolonged time to reach clinical stability
(TCS) during hospitalisation.
The aim of the present study was to evaluate: (i) the
inflammatory pattern in both blood and EBC in CAP pa-
tients on hospital admission; (ii) the relationship be-
tween pro- and anti-inflammatory cytokines (separately
in blood and EBC) and the severity of the disease in
CAP patients on hospital admission; and (iii) the rela-
tionship between pro- and anti-inflammatory cytokines
(separately in blood and EBC) and TCS in patients with
CAP.
Methods
Study design, setting and patients
This was an observational, prospective, cohort study of
consecutive patients admitted with a diagnosis of CAP
at the pulmonary and emergency medicine departments
of the IRCCS Policlinico Hospital, Milan, Italy, between
April 2010 and January 2012. The institutional review
board of the hospital approved the study (Approval ref-
erence number: 1,686) and patients signed an informed
consent. Patients ≥18 years of age and satisfying the cri-
teria of CAP were included in the study. Patients with at
least one of the following were excluded from the study:
hospital-acquired pneumonia (defined as pneumonia
that develops after 48 h of the current hospitalisation),
pneumonia that develops in patients discharged from
the hospital within the prior 14 days, chronic steroid
treatment, and unstable psychiatric or psychological
conditions.
Data collection
Patients’ management was performed according to local
standard operating procedures. The following data were
collected for each study subject on admission to hospital
by one study investigator (LM): demographics (age, gen-
der); comorbidities (active cancer, cerebrovascular dis-
ease, neurological disease, renal disease, liver disease,
type II diabetes mellitus, chronic obstructive lung dis-
ease, hypertension, chronic heart failure, coronary artery
disease, prior acute myocardial infarction); clinical signs
and symptoms (body mass index, heart rate, respiratory
rate, systolic blood pressure, diastolic blood pressure,
oxygen saturation); radiographic and laboratory findings
on admission and during hospitalisation (haematocrit,
haemoglobin, white blood cells, platelets, albumin, lac-
tates, C-reactive protein [CRP], procalcitonin [PCT]);time from symptoms onset to hospitalisation; empiric
antibiotic therapy, according to the European Respira-
tory Society guidelines [14]; and severity of disease
(pneumonia severity index [PSI] [15]), severe sepsis, se-
vere CAP, alteration of gas exchange). The length of hos-
pital stay (LOS) and in-hospital mortality were also
noted for each patient. A paper case report form was
used to collect anonymised data that have been then dir-
ectly transferred to SPSS 18.0 for MAC OS (SPSS Inc.,
USA). Quality control of the data was performed by a
study investigator (SA).
Blood and EBC sample collection
Approximately 7 ml of blood and a specimen of EBC
were collected within 24 h from hospital admission.
After blood centrifugation, serum was stored at −80 °C.
The EBC was collected for 15 min using the condensing
device R-tubeTM (Cosmed, Italy). The collection was per-
formed in compliance with the latest American Thoracic
Society (ATS)/European Respiratory Society (ERS) rec-
ommendations [11]. Patients were asked to breathe out
spontaneously through a mouthpiece and a two-way
non-rebreathing valve, which also serves as a saliva trap,
connected to the tube. Subjects wore a nose clip and
were breathing with a respiratory rate that ranged from
15 to 20 breaths/min. If the subjects salivated they were
instructed to swallow. Samples were stored at −80 °C for
no longer than 4 weeks until measurements were taken.
Microbiological analysis of respiratory samples
Microbiological examinations were performed on re-
spiratory samples (e.g. sputum and tracheobronchial as-
pirates) during the first 24 h after admission and
according to standard hospital protocols. Identification
of microorganisms and susceptibility testing were per-
formed according to standard methods [16].
Cytokine measurements
Systemic and local inflammatory responses were evaluated
measuring cytokines in both the serum and EBC samples
with a high sensitivity immunoassay kit (Randox™, United
Kingdom) and were classified as pro-inflammatory (inter-
leukin [IL]-1, IL-1α, IL-1β, IL-2, IL-6, IL-8, tumor necrosis
factor [TNF]α and interferon [IFN]γ) or anti-inflammatory
(IL-4 and IL-10). The Evidence Investigator™ Cytokine &
Growth Factors High Sensitivity Array (Randox) was used
for the simultaneous quantitative detection of multiple cy-
tokines from a single sample. The Randox Biochip (Ran-
dox) is a solid-state device containing an array of discrete
test regions of immobilised antibodies specific to different
cytokines and growth factors. A sandwich chemilumines-
cent immunoassay is employed for the cytokine array. In-
creased levels of cytokine in a specimen will lead to
increased binding of antibody labeled with horseradish
Table 1 Demographics and comorbidities of the study
population (n = 74)
Characteristics No. of patients
Demographics, n (%)
Gender, male sex 45 (61)
Age, median years (IQR) 76 (65-83)
Comorbidities, n (%)
Active cancer 8 (11)
Cerebrovascular diseases 7 (10)
Neurological diseases 16 (22)
Renal diseases 11 (15)
Liver diseases 6 (8)
Type II diabetes mellitus 14 (19)
COPD 21 (28)
Hypertension 36 (49)
Chronic heart failure 15 (20)
Coronary artery disease 19 (26)
Prior acute myocardial infarction 13 (18)
IQR 25–75 interquartile range, COPD chronic obstructive pulmonary disease
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cence signal emitted. The light signal generated from each
of the test regions on the biochip is detected using digital
imaging technology and compared to that from a stored
calibration curve. The concentration of analytes present in
the sample is calculated from the calibration curve.
Study definitions
CAP was defined as the presence of a new pulmonary
infiltrate on chest radiograph at the time of hospitalisa-
tion associated with at least one of the following: (i) new
or increased cough with/without sputum production; (ii)
fever (documented temperature, rectal or oral, ≥38.3 °C)
or hypothermia (documented temperature, rectal or oral,
<36 °C); (iii) evidence of systemic inflammation (abnormal
white blood cell count—either leukocytosis [>10,000/cm3]
or leukopenia [<4,000/cm3] or CRP or PCT values above
the local upper limit).
Severe sepsis was defined by the presence of at least
one of the following signs of organ hypoperfusion or
organ dysfunction: (i) sepsis-induced hypotension; (ii)
lactate greater than the upper limits of normal labora-
tory results; (iii) urine output <0.5 ml/kg/h for >2 h des-
pite adequate fluid resuscitation; (iv) creatinine >2 mg/
dl; (v) bilirubin >2 mg/dl; (vi) platelet count <100,000;
(vii) coagulopathy (international normalised ratio [INR]
>1.5) [17].
Severe CAP was defined according to the Infectious
Diseases Society of America (IDSA)/ATS guidelines pub-
lished in 2007 [18].
Alteration of gas exchange was defined as the presence of a
PaO2/FiO2 ratio less than 250 with at least one of the following:
(i) tachypnoea (respiratory rate >30 breaths/min); (ii) acute re-
spiratory acidosis; or (iii) accessory muscle use.
LOS was calculated as the number of days from the
date of admission to the date of discharge. LOS was cen-
sored at 14 days in an effort to capture only CAP-related
LOS.
In-hospital mortality was considered if death by any
cause occurred during hospitalisation.
Study outcome
TCS was the study outcome. A patient was considered
to have reached clinical stability when the following cri-
teria were all met in a single day during hospitalisation:
(i) improved clinical signs (cough and shortness of
breath); (ii) patient was afebrile for at least 8 h; (iii) im-
proving leukocytosis (decreased at least 10 % from the
previous day) or CRP or PCT; (iv) tolerating oral intake
[19]. Criteria for clinical stability were evaluated daily.
Statistical analysis
Data were analysed using SPSS 18.0 for MAC OS (SPSS
Inc., USA). Baseline characteristics of the population,biomarkers levels on admission, and outcome were con-
sidered for statistical analysis. Continuous variables are
expressed as median (interquartile range [IQR] 25th–
75th percentile). The difference of median (IQR) was
evaluated by the Wilcoxon–Mann–Whitney U two-
sample test. Categorical data are expressed as frequen-
cies and percentages and compared using the Pearson’s
chi-square or Fisher’s exact test where appropriate. Al-
though similar comparisons have been performed mul-
tiple times in the analysis, we decided not to correct the
level of significance to account for them, knowing that
this would have reduced the chance of type I error. We
opted for this choice in order to avoid increasing the
chance of type II error. All tests were 2-tailed and a p-
value of <0.05 was considered statistically significant.Results
Study population characteristics
A total of 74 patients (median age: 76 years; gender:
61 % male) were enrolled during the study period.
Demographics, comorbidities, physical examination, la-
boratory tests and severity of the disease on hospital ad-
mission of the study population are summarised in
Tables 1 and 2. Aetiological diagnosis of CAP was
reached in 10 (14 %) patients and the following microor-
ganisms were the most commonly isolated: Streptococcus
pneumoniae (6 patients), Legionella pneumophila (2 pa-
tients), and Mycoplasma pneumoniae (2 patients).
Among the entire study population, median TCS was
4 days, while median LOS was 9 days. One patient died.
Table 2 Physical examination, laboratory tests and severity of
the disease on hospital admission of patients with community-
acquired pneumonia (CAP) (n = 74)
Characteristics No. of patients
Physical examination, median (IQR)
Body mass index, kg/m2 24.5 (21.0–27.5)
Heart rate, beats/minute 94 (80–112)
Respiratory rate, breaths/minute 24 (18–28)
Systolic blood pressure, mmHg 135 (113–160)
Diastolic Blood Pressure, mmHg 70 (60–85)
Oxygen saturation, % 95 (91–97)
Laboratory tests, median (IQR)
Haematocrit, % 39 (34–42)
Haemoglobin, g/dl 12.8 (11.2–14.2)
White blood cells, 103/ml 10.7 (8.2–14.2)
Platelets, 103/ml 185 (149–258)
Albumin, g/dl 3.5 (3.2–3.8)
Lactates, mmol/l 1.2 (0.9–1.9)
C-reactive protein, mg/dl 11.4 (4.1–23.5)
Procalcitonin, ng/ml 1.0 (0.3–6.4)
Severity of the disease, n (%)
PSI classes IV–V 58 (78)
Severe sepsis 20 (27)
Severe CAP 21 (28)
Alteration of gas exchange 10 (14)
IQR 25–75 interquartile range, PSI pneumonia severity index
Table 3 Cytokine levels in both serum and exhaled breath
condensate on hospital admission of patients with community-
acquired pneumonia
Cytokine Cytokine level (pg/ml)
Serum Exhaled breath condensate
Pro-inflammatory
IL-1 1.11 (0.87–1.53) 0.20 (0.08–1.10)
IL-1α 0.11 (0.06–0.21) 0.11 (0.05–0.22)
IL-1b 0.96 (0.76–1.36) 0.00 (0.00–0.95)
IL-2 1.14 (0.84–1.83) 0.80 (0.00–1.24)
IL-6 28.95 (9.92–106.27) 0.00 (0.00–0.10)
IL-8 12.82 (8.10–43.81) 0.36 (0.00–0.47)
IFNγ 0.82 (0.46–2.81) 0.00 (0.00–0.16)
TNFα 5.86 (3.85–8.94) 0.00 (0.00–0.76)
Anti-inflammatory
IL-4 1.53 (1.32–1.99) 1.98 (1.55–2.39)
IL-10 1.33 (0.78–2.08) 0.27 (0.00–0.37)
Data presented as median (interquartile range)
IL interleukin, IFN interferon, TNF tumor necrosis factor
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Cytokine concentrations in both serum and EBC on hos-
pital admission are shown in Table 3.
Cytokine levels and severity of the disease on hospital
admission
A complete analysis of cytokine levels according to the
severity of the disease on hospital admission is presented
in the Additional file 1: Table SA). Briefly, levels of IL-1α
were found to be significantly higher in both serum and
EBC of patients in PSI Risk Class IV–V versus I–III.
Levels of IL-1 and IL-1α were found to be significantly
higher both in serum and EBC of patients with altered
gas exchange compared to those without. TNF-α levels
in serum and IL-1β levels in the EBC were significantly
higher in patients with altered gas exchange compared
to those without. IL-6 and IL-8 levels were found to be
significantly higher in the serum of patients with severe
sepsis compared to those without, while IL-10 was sig-
nificantly lower in the EBC of patients with both severe
sepsis and severe CAP, compared to those without.
As shown in Table 4 (Panel A and Panel B), anti- to
pro-inflammatory cytokine ratios were found to be sig-
nificantly lower in patients with severe CAP and severesepsis. The lower ratio in serum of patients with severe
infection was mainly due to a more active pro-
inflammatory profile (significantly higher levels of IL-6
and IL-8; p < 0.006 and p <0.004, respectively [Additional
file 1: Table SA]). On the contrary, the lower ratio in the
EBC of patients with severe infection was mainly due to
a less intense anti-inflammatory profile (significantly
lower levels of IL-10; p < 0.017 [Additional file 1: Table
SA]). A complete analysis of cytokine ratios according to
the severity of disease on admission is presented in
Additional file 1: Table SB.
Cytokine levels and clinical outcome
IL-6 levels were higher among patients with TCS >4 days
versus TCS ≤4 days, especially in serum (43 vs. 25 pg/
ml; p = 0.010) (see text and Additional file 1: Table SC).
Anti- to pro-inflammatory cytokine ratios were found to
be significantly lower in patients with a TCS >4 days.
Median (IQR) IL-4/IL-6 ratio in serum was 0.02 (0.01–
0.10) pg/ml in patients with a TCS >4 days versus 0.07
(0.02–0.20) pg/ml in those with a TCS ≤4 days (p =
0.027). Median (IQR) IL-4/IL-8 ratio in serum was 0.04
(0.03–0.13) pg/ml in those with a TCS > 4 days versus
0.12 (0.06–0.27) pg/ml in those with a TCS ≤4 days; p =
0.029. A complete analysis of cytokine levels and ratios
according to TCS is presented in Additional file 1:
Table SC.
Discussion
The present study indicates differences in inflammatory
patterns in the EBC and serum on hospital admission in
patients with CAP, with a high anti-inflammatory IL-4
Table 4 Significant comparisons between anti- to pro-
inflammatory cytokine ratios according to the severity of the
disease (Panel A) and the presence of severe sepsis (Panel B) in
patients with community-acquired pneumonia (CAP)
Cytokine ratio Cytokine level (pg/ml) p-value
Panel A
Severe CAP Non severe CAP
Serum
IL-4/IL-8 0.03 (0.01–0.15) 0.12 (0.04–0.22) 0.038
IL-4/IFNγ 0.90 (0.02–2.16) 1.64 (0.31–4.09) 0.047
IL-4/IL-1 1.20 (0.32–1.35) 1.60 (1.15–2.34) 0.001
IL-4/IL-1b 1.26 (0.47–1.77) 1.60 (1.20–2.24) 0.035
IL-10/IL-8 0.05 (0.02–0.16) 0.12 (0.05–0.20) 0.048
Exhaled breath condensate
IL-4/IL-1b 1.94 (1.72–2.26) 2.37 (2.02–3.36) 0.044
IL-10/IL-2 0.00 (0.00–0.29) 0.35 (0.25–0.47) 0.005
IL-10/IL-6 0.00 (0.00–0.00) 3.02 (0.58–3.82) 0.016
IL-10/IL-8 0.00 (0.00–0.41) 0.75 (0.19–1.72) 0.002
Panel B
Severe sepsis Non severe sepsis
Serum
IL-4/IL-6 0.01 (0.00–0.04) 0.07 (0.02–0.17) 0.000
IL-4/IL-8 0.03 (0.00–0.10) 0.12 (0.06–0.21) 0.002
IL-4/IL-1 1.23 (0.15–1.61) 1.55 (1.10–2.32) 0.006
IL-10/IL-6 0.01 (0.00–0.07) 0.05 (0.02–0.12) 0.017
IL-10/IL-8 0.03 (0.01–0.18) 0.12 (0.05–0.19) 0.039
Exhaled breath condensate
IL-10/IL-2 0.00 (0.00–0.21) 0.38 (0.26–0.48) 0.000
Data presented as median (interquartile range)
IL interleukin, IFN interferon
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IL-6 and IL-8 concentration in serum. The anti- to pro-
inflammatory cytokine ratio is decreased in patients with
both severe disease on admission and prolonged TCS.
This reduction seems to be due to lower levels of anti-
inflammatory cytokines in the EBC and higher levels of
pro-inflammatory cytokines in serum.
Local concentrations of both anti- and pro-inflammatory
cytokines were evaluated in the present study using the
EBC. The EBC is a standardised, non-invasive technique
that has been extensively used to collect airway lining fluid
and assess lung inflammation in several respiratory dis-
eases during the past two decades [11]. To date, only one
study compared systemic to local inflammatory response
by measuring cytokines in peripheral blood and EBC in pa-
tients with pneumonia [20]. In this latest study, authors
compared levels of TNFα and vascular endothelial growth
factor in patients with pneumonia and lung cancer, as well
as healthy controls, while we evaluated a wide range ofcytokines in a homogenous model such as CAP. One of
the major limitations of this technique is that in the ab-
sence of a comparison with BAL results we might not be
fully confident that EBC results are in fact representative
of the real inflammation of the parenchyma, rather than
inflammation of the airways.
Our analysis showed some differences in patterns of
cytokine expression in serum and EBC. However, the fact
that these are two different biological samples, along with
the absence of a control group in our study, dose not allow
us to make strong speculation on the possible presence of
two different compartments of the host inflammatory re-
sponse (lung and blood). We found high concentrations of
the anti-inflammatory IL-4 in EBC on admission, while in
serum pro-inflammatory activation was prominent. An
anti-inflammatory activation in the lungs, through the ex-
pression of the anti-inflammatory IL-10, has already been
reported by van der Poll and colleagues [21] in a mouse
model of S. pneumoniae pneumonia.
High levels of serum pro-inflammatory cytokines
showed a direct relation with the severity of the disease on
admission. These data support the hypothesis that severe
infection is a consequence of the dis-regulation between
pro- and anti-inflammatory pathways [8, 22]. Our results
are also consistent with previous observations [9, 23],
which describe an association between systemic levels of
pro-inflammatory cytokines and severity of CAP. Paats
et al. [23] found that in the BAL of patients with severe
CAP, both IL-6 and IFN-γ were significantly increased
compared with healthy individuals. Similarly, we found
higher levels of the pro-inflammatory cytokine IL-1β in
the EBC of patients with altered gas exchange and lower
levels of the anti-inflammatory cytokine IL-10 in the EBC
of patients with severe sepsis and severe CAP.
Despite a consistent number of observations, the role
of pro- and anti-inflammatory mediators considered on
their own is still unclear. Pro-inflammatory molecules
are part of the host defence mechanisms against infec-
tion, but they also play a role in the “cytokine storm”
that may trigger severe sepsis and acute respiratory dis-
tress syndrome. Similarly, anti-inflammatory molecules,
at an early stage, may hamper the effective clearance of
the infection, but they also have a role in the modulation
and prevention of an excessive immune response. In this
scenario, what seems to be important is the relationship
between anti- and pro-inflammatory mediators, which
can be evaluated through the anti-/pro-inflammatory
cytokine ratios. An adequate response to infection
should aim at a timely balance between the two, while
an imbalance leads to an inadequate or excessive host
defensive response. Our results are consistent with this
hypothesis. The anti-/pro-inflammatory cytokine ratios
were significantly lower both in serum and EBC of pa-
tients with severe CAP and severe sepsis, compared to
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ratio were also found in patients who showed a prolonged
TCS compared to patients with a shorter one. Similar re-
sults were reported by Chou and colleagues [13] in 25 pa-
tients with P. jirovecii pneumonia: a pro-inflammatory
imbalance in the pro-/anti-inflammatory cytokine ratio
was described in the BAL of patients with more severe
respiratory failure and worse clinical outcomes. It is note-
worthy that in our patients with severe infection the lower
serum ratio was mainly due to a more active pro-
inflammatory profile, while the lower EBC ratio was
mainly due to a less intense anti-inflammatory reaction.
Different limitations of the present study should be ac-
knowledged, including: (i) the absence of a control group
without CAP to better interpret cytokine values in the
EBC; (ii) the fact that measurements from EBC were not
compared with results from BAL and, thus, EBC results
might not be fully representative of the extent of inflam-
mation in the lungs; (iii) the absence of timing of sample
collection (EBC and serum were collected only on hos-
pital admission) and therefore not allowing a longitu-
dinal evaluation of the inflammatory patterns; (iv) the
isolation of the microorganism causing pneumonia only
in a small percentage of patients, not allowing any
speculation regarding the association between pathogen
and inflammatory response; (v) missing data, in view of
the small sample size, regarding the relationship between
cytokines profile and other early and long-term out-
comes, such as mortality during hospitalisation.
Our study is strengthened by the use of EBC instead
of BAL, which allowed us to enrol patients from mild to
severe CAP. This aspect and the fact that we did not use
important exclusion criteria increase the generalisability
of our results. Furthermore, we conducted a comprehen-
sive evaluation of cytokines, including both anti- and
pro-inflammatory mediators.
Conclusions
In conclusion, CAP patients with severe disease on hos-
pital admission and prolonged TCS showed an imbal-
ance in the pro-/anti-inflammatory cytokines ratio
toward a pro-inflammatory profile. A deeper knowledge
of the pro- and anti-inflammatory mechanisms may help
to evaluate new therapeutic approaches.Additional file
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